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Gold Nanoparticle-Based Colorimetric Biosensors 
H. Aldewachi, a† T. Chalati,a,b† M.N. Woodroofe,a N. Bricklebank,a B. Sharrack,c  P. Gardinera 
 
Gold nanoparticles (AuNPs) provide excellent platforms for the development of colorimetric biosensors as they can be 
easily functionalised, displaying different colours depending on their size, shape and state of aggregation. In the last 
decade, a variety of biosensors have been developed to exploit the extent of colour changes as nano-particles (NPs) either 
aggregate or disperse, in the presence of analytes. Of critical importance to the design of these methods is that the 
behaviour of the systems has to be reproducible and predictable. Much has been accomplished in understanding the 
interactions between a variety of substrates and AuNPs, and how these interactions can be harnessed as colorimetric 
reporters in biosensors. However, despite these developments, only a few biosensors have been used in practice for the 
detection of analytes in biological samples. The transition from proof of concept to market biosensors requires extensive 
long-term reliability and shelf life testing, and modification of protocols and design features to make them safe and easy to 
use by the population at large. Developments in the next decade will see the adoption of user friendly biosensors for 
point-of-care and medical diagnosis as innovations are brought to improve the analytical performances and usability of the 
current designs. This review discusses the mechanisms, strategies, recent advances and perspectives for the use of AuNPs 
as colorimetric biosensors.  
Keywords: biosensors, colloids, gold nanoparticles, nanotechnology, surface plasmon resonance, enzymes, quantification. 
Introduction  
Gold nanoparticles (AuNPs) (derived from the Greek word 
nanus, meaning dwarf) are currently used in a variety of 
biomedical applications, due to their size-dependent chemical, 
electronic and optical properties. The pertinent physical 
properties include a high surface-to-volume ratio, 
biocompatibility, in addition, the dimensions of the metal NPs 
are comparable to those of biomolecules such as proteins 
(enzymes, antibodies) or DNA, whose dimensions are in the 
range of 2-20 nm thus imparting a structural compatibility of 
these two classes of material.1,2 Moreover, the multitude of 
available shapes of AuNPs allow easy surface functionalisation 
with probes and other compounds of interest, thus making 
them amenable to a variety of detection modalities and 
techniques as shown in (Fig. 1). 3–5 
Modern scientific evaluation of colloidal Au began with 
Michael Faraday’s work in the 1850s, which recognised that 
the colour observed was due to the size of the Au particles.6 
Faraday’s rationale in investigating colloidal phenomena 
followed his interests in the interaction between light and 
matter. Technological advances in the development of 
molecular beam techniques have made it possible to study and 
determine the morphological, physical and chemical 
properties of AuNPs.7,8  
 
The chronology of the historical events that led to the 
development of nanotechnology is listed in (Table 1). 
Colloidal Au has been used since the last century for the study 
of cerebrospinal fluid by using the Lange reaction in which 
colloidal gold reaction was used to detect infection of the 
central nervous system for the early diagnosis and prognosis of 
obscure neurological conditions. Briefly, a series of spinal fluid 
samples diluted in aqueous saline solution were treated with a 
colloidal gold solution and the reaction was allowed to stand 
for 24 hours to get a final reading (Fig. 2). Depending on the 
pathological conditions investigated, a certain pattern of 
colour change of the colloidal auric solution occurs. This 
application may have been the first recorded practical 
application of extremely small gold particles for biosensing.9  
The use of AuNPs for colorimetric sensing exploits the interparticle 
distance dependent localised surface plasmon resonance (LSPR) 
property.10–12 Biological processes and biomolecular-interactions 
can be monitored because they can be used to control the 
dispersion and aggregation of the NPs. Depending on the size of the 
AuNPs, controlled aggregation of the particles can result in colour 
changes,13–15 from pink to violet to pale blue. This phenomenon has 
been used in home pregnancy tests and in analyses for specific gene 
sequences16,17 and for colorimetric detection of a variety of 
analytes.18–20 It is the anticipated colour changes during aggregation 
(or dispersion of aggregates) that provide a platform for 
colorimetric detection using AuNPs as signal transducers.21,22 The 
aggregated AuNPs not only give different colours from dispersed 
AuNPs but also different surface enhancement abilities of Raman 
scattering. 23 
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Typically, NPs biosensors consist of immobilised ligand or a 
biological substrate which undergo transformation in the presence 
of an analyte.24 The analyte induces a modification in the substrate 
composition or conformation, thus imparting a change to the  
environment of the NPs, resulting in changes in the aggregation 
status of NPs leading to detectable colour changes.25–27  In order to 
develop efficient and reliable sensors, it is essential to improve both 
the recognition and transduction processes through the 
development of novel materials. Nanomaterials can be fabricated 
to produce platforms with improved signal to noise (S/N) ratios by 
miniaturisation of the sensor elements.28  
Traditionally, analyte detection and quantification involve 
recording the absorbance or fluorescence emitted from 
substrates modified with chromogenic or fluorogenic reporter 
molecules. Fluorescence resonance energy transfer (FRET) 
substrates or indirect sensor systems depend on sensing the 
reactions of unmodified substrates to produce a detectable 
spectroscopic signal. Although these approaches, in general, 
are adequate for many applications (commercial assays kits 
are available), there is a need to improve sensitivity for a 
variety of other applications.29–33 
NPs-based assays have now made it possible to measure minute 
changes in enzyme activity with high accuracy and precision.34 A 
variety of NPs-based sensing systems have been developed with 
varying degrees of success and reliability. These sensing systems are 
valuable tools for the measurement of enzyme activity in real time 
and can be used for high-throughput screening of enzyme activity 
and in drug discovery.35 This review includes a brief introduction to 
the physical phenomenon (i.e., colours) associated with AuNPs and 
their aggregation, discussion of the inter-particle forces of AuNPs 
and factors controlling AuNPs colloidal stability and aggregation, 
along with general strategies for the stabilisation or aggregation of 
the colloidal particles. The focus is on the mechanisms and 
strategies of biosensing assays, the common challenges, current 
trends in the field, real sample analysis, and exploitation of the 
anisotropic properties of AuNPs as colorimetric probes.36–38 
 
1. Localised surface plasmon resonance (LSPR) of 
AuNPs 
The fundamental concept underpinning light absorption by metal 
NPs is the coherent oscillation of the conduction band electrons 
induced by the interacting electromagnetic field.26 In the case of 
AuNPs, the oscillations involve the 6s electrons in the conduction 
band. The boundary and surface effects become more dominant 
when the particle dimensions become less than 100 nm. The optical 
properties of small metal NPs are dominated by the collective 
oscillation of the conduction electrons.39 When the incident photon 
frequency is resonant with the collective oscillation of the 
conduction band electrons, the radiation is absorbed to give an 
absorption band. This phenomenon is known as localized surface 
plasmon resonance (LSPR). 
Unique LSPR properties and the colours associated with the 
aggregation and dispersion of the colloidal particles make AuNPs  
Surface 
plasmon 
resonance 
Surface 
functionalisation 
Fluorescence 
Luminescence 
High 
adsorption 
coefficient  
Aggregated AuNPs Dispersed AuNPs 
Figure 1 Physical and chemical properties of AuNPs and schematic illustration of AuNPs (aggregation/dispersion) colorimetric based 
detection systems. The unique properties of AuNPs, such as their high absorption coefficient, scattering flux, luminescence and 
conductivity, as well as their ability to enhance electromagnetic fields, quench (or enhance) fluorescence and catalyse reactions, provide 
numerous possibilities to exploit these particles for sensing and quantification purposes.10,186,187 
Target analyte 
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ideal colorimetric reporters for biological analysis.  
 
 
Table 1 Chronological order of events leading to the different uses of AuNPs.  
 
It has been found that the electromagnetic coupling of NPs 
becomes effective when the inter-particle distances are less than 
2.5 times their individual diameters. 48,49 Aggregation can induce the 
coupling of the AuNPs plasmon modes, producing a red shift and 
broadening of the SPR band, associated with the longitudinal 
resonance in the optical spectrum.8 As a result, aggregation usually 
changes the original red colour of the AuNPs dispersion into purple 
or blue.50 The strong enhancement of the localized electric field 
within the interparticle spacing, broadens and red shifts the SPR 
spectra. Interparticle plasmon coupling is rather complex and 
dependent on a number of factors such as aggregate morphology 
and NPs density.19  
Aggregation or dispersion of NPs can be initiated by changes in the 
external environment. These stimuli can cause the AuNPs to either 
aggregate or disperse, accompanied by a shift in the absorption 
spectrum of the AuNPs, and consequently the colour of the 
colloidal solution changes. The extent of aggregation/re-dispersion 
is proportional to the absorption peak shift, and thus the extent of 
signal change is quantifiable offering a direct measure of the effect 
of the inducing agent e.g., an active enzyme.51 For AuNPs in the size 
range of 13-300 nm, progressively increased aggregation is 
characterized by a gradual decrease of the plasmon peak at 520 nm 
and the appearance of a new peak between ∼600-700 nm with 
colour change of the resultant solution ranging from red to purple 
or blue depending on the degree of aggregation (Fig. 3A) whereas 
the band at 520 nm is the SPR of the spherical AuNPs, however with 
aggregation the new band appear 600 – 700 nm appears (see Fig. 
3B). In some cases, the LSPR spectrum may be featureless and the 
solution could turn colourless, showing extreme aggregation, when 
the plasmon band shifts into the infra-red (IR) region where most 
visible light is scattered.  
The sensitivity of a colorimetric assay is dependent on the molar 
extinction coefficients of the NPs plasmon bands, which are in turn 
determined by the material composition and particle size.21,52 
Larger NPs offer higher sensitivity as their surface plasmons have 
higher molar extinction coefficients. It has been found that the 
molar extinction coefficients triple in magnitude when the AuNPs 
size increases from 4 to 35 nm.53–55 The ratio of maximum 
absorbance at the longer and original wavelength (e.g., A600/A520 for 
AuNPs) is often used to quantify the extent of aggregation and it is 
known as an aggregation parameter.56,57  
2. Colloidal AuNPs stabilization 
A major consideration in the use of AuNPs in a variety of biomedical 
applications is that the stability of colloidal solutions and changes in 
aggregation should be controllable and predictable. Stability of the 
gold solutions can be achieved by the introduction of molecules 
that interact with AuNPs through bonding and/or electrostatic 
interactions.58,59 
 For this purpose, various biological probes have been used for the 
stabilization and/or functionalisation of colloidal AuNPs; these 
include nucleic acids, enzymes, receptors, lectins, antibodies and 
superantigens.60–64  
 
 
Figure 2. The reaction of Lange gold chloride test on the cerebrospinal fluid 
in congenital syphilis. Reproduced from Ref 9 
 
2.1 DLVO and non-DLVO forces 
The stabilisation phenomenon of Au particles in a well-defined and  
controlled assembly has been generally explained by the Derjaguin-
Landau-Verwey-Overbeck (DLVO) theory,65,66 usually expressed in 
Period Inventors Achievement Ref 
4th Century A. 
D 
Romans Lycurgus Cup 40 
17th Century Andreas 
Cassius 
"Purple of Cassius" for glass 
staining 
41 
1857 Faraday Scientific evaluation of 
AuNPs colour change 
6 
1902 Zsigmondy Invention of ultra-
microscope 
42 
1908 Mie Mie theory – Fundamental 
understanding of the NPs 
interactions with 
electromagnetic radiation 
43 
1951-1973 Frens-
Turkevich 
Synthesis of AuNP 
preparations 
44,45 
1960 Feynman Mention of NPs in a famous 
lecture in which he 
propounded that "There's 
plenty of room at the 
bottom" meaning at the 
nanoscale. 
46 
1971 Faulk and 
Taylor 
First biomedical use in 
immunochemical staining  
47 
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terms of the balance between attractive Van der Waals forces and 
the repulsive electrostatic interactions, to describe the colloidal 
stability of aqueous dispersions.66 The DLVO theory accounts for the 
potential energy variations that occur when two particles approach 
each other with the resultant net attraction and repulsion forces as 
a function of interparticle distance.65–67 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
According to this theory, the net interaction potential G between 
two AuNPs is determined by the Van der Waals attraction (G vdW) 
and electrostatic repulsion (G elec) values, 
ΔG = ΔG Van der Waals +Δ G electrostatic ………………………… (1) 
Although there is considerable body of research information in 
support of the DLVO model, it has long been understood that the 
classical DLVO theory does not completely explain the results across 
different experimental settings. For example, the prediction of the 
model is contradicted when two particles or surfaces approach 
closer than a few nanometres. 68 In this instance, non-DLVO forces 
such as different hydrophobic, steric and solvation forces come into 
play. As a result, the traditional DLVO theory has thus been 
extended to include the latter as described in the following 
equation:  
ΔG = ΔG Van der Waals attraction + ΔG electrostatic repulsion + ΔG 
non-DLVO forces ………………………………………………. (2) 
 
2.2 Stabilization strategies 
Stabilization of colloidal Au is achieved either electrostatically or 
sterically by the use of various surface ligands or by a combination 
of both electrostatic and steric repulsion forces (Fig. 4 A-C) 58,69–71.  
In aqueous solutions, zero charged bare AuNPs tend to aggregate 
because of Van der Waals attractive forces. The fundamental 
importance in the design of AuNPs-based colorimetric sensing 
platforms is to achieve colloidal stabilization by introducing 
repulsive forces between the particles in order to prevent colloidal 
aggregation in the absence of the target analyte. AuNPs 
stabilization or aggregation depends on the net potential between 
interparticle attractive and repulsive forces.58,69–73 
Further control of AuNPs stability is usually achieved through the 
introduction of colloidal stabilizers by using chemical coupling 
methods (e.g., Au–thiol, Au–amine), electrostatic and physical 
adsorption, etc. Common colloidal stabilizers include charged small 
molecules, polymers and polyelectrolytes. In the case of 
electrostatic stabilization (Fig. 4A), each particle carries a "similar" 
electrical charge, and together with the counter ions in the 
medium, they form a repulsive electric double layer that stabilizes 
the colloid against Van der Waals attractive forces.74 Since the 
thickness of the electrical double layer is governed by the bulk ionic 
strength of the liquid medium, electrostatic stabilization is highly 
sensitive to salt concentration.72,73  
With steric stabilization (Fig. 4B), ligands adsorbed or bound to the 
particle surfaces form a physical barrier that prevents the particles 
from crowding. The strength of this stabilization effect is not 
sensitive to change in ionic strength but determined by molecular 
size and capping density. Both electrostatic and steric stabilization 
are known as the electrosteric effect (Fig. 4C). Biomolecules, for 
example, drugs, peptides, nucleic acids, and proteins that are highly 
charged and have polymeric properties can be effective stabilizers. 
69–71  
The common approach for the use of AuNPs in colorimetric assays 
involves the preparation of a stable colloidal solution, whose 
stability is disrupted upon the addition of the analyte with resultant 
colour change75. The mechanisms involved in interactions between 
the colloidal particles leading to aggregation or dispersion of the 
particles are given below:  
(i) formation of interparticle bond crosslinking (CL), (ii) removal of 
colloidal stabilisation leading to non-crosslinking (NCL) aggregation, 
(iii) There is also another colorimetric sensing strategy that does not 
rely on changes in NPs stability, but on morphology changes 
induced by a chemical reaction on the surface of the metal NP 
(AuNPs based plasmonic ELISA sensors). 
 
3. Interparticle crosslinking (CL) aggregation 
Interparticle CL aggregation is a mechanism in which AuNPs are 
brought together through the formation of linkages between the 
individual particles. This occurs either by using crosslinker 
molecules that have two binding sites linking two AuNPs to each 
other (i.e., peptides with thiol and/or guanidine anchors) (Fig. 5) or 
by the direct interaction (without crosslinkers) such as antigen - 
antibody interactions and DNA hybridisation.76 In either case, 
specific binding forces (H-bonding, electrostatic interaction, metal–
ligand coordination, etc.) associated with biological recognition 
events (DNA hybridisation, ligand–DNA binding, DNA cleavage, etc.) 
overcome the interparticle repulsive forces (electrostatic and/or 
steric repulsion) with resultant typical aggregation.11 Table 2 
summarises typical applications of AuNPs-based colorimetric 
biosensing assays that rely on interparticle CL aggregation 
(B) 
(A) 
    a          b          c         d         e          f           j         h        
Figure 3. A) The gradual colour change as functionalised AuNPs are exposed 
to increasing enzyme activity resulting in increased aggregation, B) Spectral 
changes of AuNPs solutions after incubation with increasing enzyme activity 
(incubation of peptide capped AuNPs with the target enzyme for 10 minutes 
at 37°C). this figure has been adapted from ref 100 with permission from 
Elsevier. 
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mechanism. The first platform for the detection of target analytes 
relies on the presence of crosslinkers that bind to sites on the 
AuNPs surface (Fig. 5). This platform (Fig. 5A) has also been utilised 
for the detection of a variety of biological molecules.77–81 In 
contrast, already crosslinked AuNPs aggregates can also be 
harnessed to detect analytes that cleave the crosslinkers and this 
leads to redispersion of the AuNPs aggregates (Fig. 5B). A reverse 
colour change (blue-to-red) occurs in this case.  
Liu and his colleagues pioneered this sensing strategy.82–84 
Laromaine et al. (2007) applied a similar strategy for the detection 
of protease activity. In their assay, the particles were modified with 
a short protease substrate terminated with an Fmoc-group that 
causes the particles to aggregate. When cleaved by the target 
protease the Fmoc group was removed and the particles were re-
dispersed, enabling detection of thermolysin down to 90 zg/mL.56 
 
 
Figure 4. Schematic illustration of NPs colloidal stabilisation: A) Electrostatic, 
B) Steric, and C) Electrosteric mechanisms. 
 
 
 
 
 
 
 
A variation of the CL aggregation method relies on biological 
transformation of molecules that are not crosslinkers into 
crosslinkers (or vice versa) or modification of ligand bound AuNPs 
to induce either aggregation or dispersion of the AuNPs (Fig. 6).  
Typical examples of the use of this modification of crosslinkers 
include protease detection assays, in which a protease degrades a 
peptide linker followed by dispersion of the AuNPs aggregates.85  
A similar strategy has also been applied to the detection of kinase, 
beta-lactamase and phosphatase.86–88 Detection of kinase activity is 
a classic example of assays that involve the modification of receptor 
functionalised AuNPs.89 In this approach different forms of 
functionalised AuNPs are utilized, one is avidin modified AuNPs and 
the second is the pentapeptide (CALNN) capped AuNPs decorated 
with γ-biotin-ATP, which when treated with a phosphatase enzyme 
results in the binding of biotinylated substrate to the avidin 
modified NPs.89 
Interparticle CL aggregation can also take place without crosslinkers 
(Fig. 7), especially when the AuNPs are functionalised with two 
different types of ligands that are complementary to each other. 
For example, DNA base-pair recognition was exploited for the 
coupling of DNA-modified NPs to each other by hybridisation with 
complementary linker strands. This approach has been used as 
probes for the detection of endonuclease (DNase I) activity and its 
inhibitors.90 Double-stranded (ds) DNA strands break down into 
single-stand (ss) DNA, resulting in the separation of AuNPs followed 
by a bluish-purple to red colour change. Alternatively, the click 
chemistry reactions-based covalent bonding, especially Cu(I)-
catalysed 1, 3-dipolar cycloaddition of azides and alkynes (CuAAC), 
has been widely used in the design of CL colorimetric nanosensors. 
In this strategy, AuNPs were typically modified with azide and 
alkyne groups by the ligand exchange reaction, and thus the 
existence of Cu (I) would trigger the CuAAC reaction and then 
crosslink the azide-AuNPs and alkyne-AuNPs to cause their 
aggregation. This aggregation of NPs leads to the color change of 
AuNPs from red to blue, and the status of aggregation can be 
correlated to the concentration of Cu (I).91 (Table 3) displays 
different sensing platforms that use the CL aggregation mechanism 
without crosslinkers and some representative target analytes. 
In summary, AuNPs-based colorimetric bioassays, which utilize 
interparticle CL aggregation mechanism, rely on interparticle forces 
and sometimes chemical interactions. This aggregation mechanism 
is mainly employed for targets that can be directly or indirectly 
modified such that they form interparticle bonds. This type of assay 
is mainly limited to cases in which the analytes and/or ligands have 
at least two binding sites. AuNPs aggregation by interparticle CL is 
sometimes a time-consuming process requiring several hours 
before aggregation and colour change are complete. Aggregation is 
mainly driven by random collisions between NPs with relatively 
slow Brownian motion.60 In addition, this interaction is hampered, if 
the probes have poorly accessible substrate ligands sites, thus 
resulting in long detection times because of slow enzyme 
kinetics.82–84  
 
4. Non-crosslinking (NCL) aggregation  
To overcome the difficulties associated with the CL based AuNPs 
aggregation, an alternative approach to control AuNPs aggregation 
by harnessing the ability of AuNPs to interact without actual bond 
formation may be desirable. This strategy eliminates the CL 
requirement for multiple binding sites in order to link the AuNPs 
thus making it possible to use a facile experimental design. In such a 
system, AuNPs aggregation is induced by the stronger interaction 
Figure 5. Schematic illustration of targeted substrates detection by binding to 
AuNPs using crosslinkers A) Addition of the crosslinker results in the aggregation of 
the AuNPs with the colour of the colloidal solution changing from red to blue.  B) 
Removal of the crosslinker with resultant dispersion of aggregated AuNPs and 
accompanying colour change from blue to red. 
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between ligands and target analytes, accompanied with the release 
of the ligand or part of it from the surface of NPs, without the 
formation of interparticle bonds, allowing real-time measurement 
of enzyme activity in contrast to the relatively slow process induced 
by inter-particle CL. Sato and his colleagues pioneered the use of 
this strategy for the detection of polynucleotide 
polymorphisms.52,60,92 When a target polynucleotide is 
complementary to the ligand in sequence and chain length, it will 
hybridise to the DNA onto the AuNPs, this in turn alters NPs 
resistance to salt-induced aggregation.22 Examples of NCL 
aggregation mechanism and some representative analytes are listed 
in (Table 4).  
Liu et al. designed a highly sensitive and selective rhodamine B-
functionalised gold nanoparticle (RB-AuNP) -based assay with dual 
readouts (colorimetric and fluorometric) for monitoring the level of 
AChE and inhibitor screening. AChE is able to hydrolyze its substrate 
acetylthiocholine to generate thiocholine, which is comprised of a 
thiol moiety and a positively charged group. The thiol group shows 
high affinity toward AuNP to induce a partial replacement of the 
fluorescent ligands such as rhodamine B from AuNP surfaces. At the 
same time, the positively charged tail groups interact with the 
negatively charged-ligand residues on AuNP surfaces, causing 
aggregation of AuNPs and the change of solution colour.93 
 
 
Figure 6 Schematic illustration of enzymatic activity detection that 
transforms the crosslinker to non crosslinker or vice versa: A) Conversion of 
non crosslinker to crosslinker and accompanying colour change from red to 
blue. B) Conversion of crosslinker to non-crosslinker and accompanying 
colour change blue to red.  
 4.1. Modification of electrostatic surface stabilisation 
Electrostatic stabilisation of AuNPs by small charged moieties, such 
as citrate-capped AuNPs, undergo aggregation when surface 
charges are screened by the addition of salt, making it possible for 
the charged ligands to be displaced by uncharged species or 
neutralized by oppositely-charged species (Fig. 8a). Luo et al. 2009 
found that digested elements of DNA have superior ability over 
intact DNA to bind to unmodified colloidal AuNPs solution at high 
salt concentration, and to stabilise them electrostatically.94 Without 
the nucleases, unmodified AuNPs turn blue due to aggregation at 
high salt concentration, whereas the particles are stabilised in the 
presence of nuclease and its substrates and remain red. 
Recently, using the same principle, Cao and co-workers have 
developed a sensitive nuclease sensor in which positively charged 
cysteamine was used to stabilise AuNPs by electrostatic repulsion 
differentially in the presence and absence of thrombin.95 This 
platform has been validated for the detection of other enzymes or 
monitoring enzymatic reactions in which the reactant and product 
differentially affect the surface charge properties of the citrate-
capped AuNPs and thus the stability of the colloidal solution.96–98  
 
 
Figure 7 Schematic illustration of receptor modification mechanisms: (A) 
Modification of the receptor on the surface of NPs (Au2) into nonreceptor 
thus preventing aggregation and colour change in the colloidal solution. (B) 
Modification of the non- receptor on the surface of NPs (Au2) into receptor 
by enabling aggregation and thus colour change red to blue. 
  
 
4.2. Factors affecting (electro) steric stabilisation  
4.2.1. Removal of ligand stabilisers  
Another platform that uses the NCL aggregation mechanism 
involves ligand-modified AuNPs that are electrosterically stabilised 
(Fig. 8b). Generally, ligands are bound to the NPs through covalent 
bonds (S-Au, N-Au, etc). Changes in the NPs solution are induced by 
the strong binding or interaction between ligands and target 
analyte, such that the system becomes so destabilised when the 
coupled ligand or part of it is cleaved, resulting in diminished or 
abolished electrosteric stabilising forces thus causing NPs 
aggregation. Proteases represent a group of enzymes that are 
frequently detected by removing peptide ligands on AuNPs 
enzymatic cleavage,84 followed by subsequent aggregation and 
colour change to detect the presence of the protease. Recently an 
optimized NCL colorimetric assay for the measurement of 
dipeptidyl peptidase-IV activity by coupling cleavable peptide 
ligands to the AuNPs surface.100 
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4.2.2. Conformational changes of charged ligands  
Another platform that employs the NCL aggregation mechanism 
relies on the change in colloidal AuNPs stability upon ligand 
conformational changes on the AuNPs surface (Fig. 8c). Wu and co-
workers utilised this strategy for screening of diamine oxidase  and 
its inhibitors by decorating calixarene derivative (pSC6) capped 
AuNPs with a charged hexanediamine (HDM) group.101 here, 
cationic substrate (HDM) functioned as a coagulant of pSC6-coated 
AuNPs with anionic sulphite−group surface charges, while oxidised 
HMD lost one of its charged terminals, thereby preventing 
aggregation of the AuNPs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In NCL aggregation systems, as soon as interparticle repulsive forces 
are insufficient to stabilise the NPs, Van der Waals attraction forces 
dominate with resultant aggregation.96 The loss of colloidal 
stabilisation, often induced by electrolytes, can be achieved by 
eliminating surface charges and surface-grafted (charged) polymers, 
and by target-induced charged ligand conformational changes.102 
AuNPs aggregation that results from charged ligand conformational 
transformation is more complex. Surface charge characteristics e.g., 
charge intensity, the extent of related counter ions and entropy 
factors are key considerations in these systems. This necessitates 
comprehensive understanding of the effects of charged ligand 
conformations on colloidal stability and state of aggregation.  
Compared to the behaviour of interparticle CL aggregation systems, 
the NCL aggregation mechanism has many desirable characteristics. 
Primarily, neither an interparticle bio recognition nor target 
analyte/receptor with multiple binding tags is needed. 
Furthermore, aggregation induced by the NCL process provides 
quick detection, often offering relatively short assay times, in the 
order of a few minutes.103 Once the inter-particle repulsive forces 
are significantly weakened, the inter-particle attractive Van der 
Waals forces predominate leading to rapid aggregation.60,104,105 
High ionic strength solutions are frequently utilised to adjust AuNPs 
stability and aggregation in NCL systems. However, it is important 
to determine the appropriate salt type and strength in order to 
obtain optimum assay performance. It should be noted that in 
some situations, certain salt types, and/or concentrations are 
undesirable or incompatible for the required signal development, 
therefore choosing a salt that has no effect on the biomolecular 
activity or a compromise between measurement performance and 
AuNPs stability/aggregation are essential.11 
 
5. Seedless production of AuNPs  
Another platform for the development of sensitive and simple 
optical methods is based on the seedless production of AuNPs. 
AuNPs are usually synthesized by using a reducer without the 
addition of NPs seeds and stabilising agent.106 Baron et al. utilised 
the neurotransmitters: dopamine, L-DOPA, adrenaline and 
noradrenaline to mediate the generation and growth of AuNPs. The 
plasmon absorbance of the AuNPs allowed the quantitative 
colorimetric detection of the neurotransmitters and was also used 
to detect the activity of tyrosinase.107 The production of AuNPs by 
the neurotransmitters enabled the measurement of the activity of 
the tyrosinase enzyme that catalyzes the O2-induced hydroxylation 
of tyrosine to L-DOPA. The latter product induces the development 
of AuNPs aggregation and colour change from colourless to red (Fig. 
9). 
 
 
Figure 9. Colour changes of the AuNPs formed in the presence of different 
concentrations of dopamine (a) 0, (b) 2.5 × 10-6, (c) 5 × 10-6, (d) 8 × 10-6, (e) 1 
× 10-5, (f) 1.5 × 10-5, and (g) 2 × 10-5 M. This figure has been adapted from ref 
107. Copyright (2005) American Chemical Society. 
 
 
 
 
 
 
 
 
Figure 8. Non-crosslinking mechanisms: A) Aggregation was controlled by the 
electrostatic forces (I) loss of electrostatic forces leads to loss of the electrical 
repulsion and inducing the aggregation: NPs suspension colour red to blue. (II) 
Acquisition of electrostatic forces that induce repulsion and aggregates 
dissociation: NPs suspension colour blue to red. 
B) Aggregation controlled by the steric (or electrosteric) forces (I) loss of steric 
repulsion forces leads to the aggregation: NPSs suspension colour red to blue. (II) 
Vice versa, acquisition of steric repulsion forces that induces the aggregates 
dissociation: NPs suspension colour blue to red 
C) Aggregation controlled by the conformation of the steric (or electrosteric) agent 
(I) conformation leads to the loss of steric repulsion forces and thus to the 
aggregation (II): NPs suspension colour red to blue. (III) Vice versa, case of 
conformation leads to the acquisition of steric repulsion forces, which induce the 
dissociation of the aggregates: NPs suspension colour blue to red. 
ARTICLE Journal Name 
8 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx 
Please do not adjust margins 
Please do not adjust margins 
 
 
 
6. High resolution multicolour nanoparticles 
Gold nanoshells containing a silver alloy have also been used as 
nanosensors in this type of detection scheme. Gao and coworkers 
designed a high-resolution colorimetric protocol based on 
gold/silver core/shell nanorod for visual readout of alkaline 
phosphatase (ALP) activity by the naked-eye (Fig. 10). The method, 
based on the enzymatic reaction, assisted silver deposition on gold 
nanorods to produce colour change, which was dependent on ALP 
activity. Upon target incubation with the substrate, ascorbic acid 2-
phosphate was hydrolysed to produce ascorbic acid, which in turn 
reduced silver ion to metallic silver coating on the gold nanorod, 
thereby resulting in a perceptible colour changes.108 Colorimetric 
AuNPs methods that have been developed for this application are 
summarized summarized in Table 5.  
 
 
 
Figure 10. Schematic diagram of the high-resolution colorimetric assay for 
sensitive visual readout of phosphatase activity based on gold/silver 
core/shell nanorod. This figure has been adapted from ref 107. Copyright 
(2014) American Chemical Society. 
 
 7. Colloidal nanoparticle-based plasmonic ELISA 
sensors and Immunoassays 
A new trend has been the use of NPs with different morphology and 
composition as a way to tune the LSPR properties of the 
nanosensors. This approach is also known as single particle 
morphology-based methods.109–111  For example, Stevens et 
al. developed a new LSPR assay in which the signal is inversely 
proportional to the analyte concentration; that is, a lower 
concentration of analyte induces a larger LSPR shift. This LSPR assay 
is based on the growth of Ag crystals in the presence of Au 
nanostars, whose absorption band is in the NIR region.109 The 
colorimetric signal of plasmonic nanosensors can be greatly 
amplified by controlling the amount of gold ions on AuNPs with 
hydrogen peroxide generated by the enzyme glucose oxidase (Fig.  
11). De la Rica and Stevens (pioneered the development of this 
strategy and employed it for the detection of prostate specific 
antigen (PSA), HIV-1 capsid antigen p24, gp 120 and urease enzyme 
activity (Table 6).111–113 
 
Liu and coworkers recently reported a wash–free homogeneous 
plasmonic colorimetric immunoassay combined with the controlled 
growth of AuNPs in aqueous solutions.114 In this strategy, the inter-
particle spacing in the protein–AuNP oligomers was modulated by 
the controlled growth on the AuNPs aggregate. Upon the gold 
growth, the particle size was enlarged and the inter-particle 
distance decreased, thereby inducing a visible optical transition. 
With this approach, the in vitro detection of cancer biomarkers (e.g. 
CEA) in serum samples from patients’ needs only 30 s by the naked 
eye. Because of its rapid and convenient sensing advantages, this 
resulted colorimetric immunoassay may allow the timely disease 
diagnosis. 
 
 
Figure 11 Scheme of the proposed signal-generation mechanism by means 
of enzyme-guided crystal growth. In the absence of the analyte, the 
reduction of gold ions with hydrogen peroxide occurs at a fast rate, and 
quasi-spherical, non-aggregated gold nanostars are blue in colour. this figure 
has been reproduced from ref 109 with permission from Nature Publishing 
Group. 
 
 
8. Future prospects and challenges in AuNPs-
based nanosensor development 
Although a variety of colorimetric nanosensors have been 
developed in laboratory settings, several aspects related to their 
practical application have not yet been addressed. Transforming 
these sensors into point of care devices awaits further 
development. Key factors that have to be addressed include 
improved resistance to fouling of the sensors and degradation of 
the organic probes, in addition, coupling of the biomolecular ligands 
to the NPs must be carefully controlled in order to avoid 
denaturation and loss of reactivity.115 The production of NPs for 
biosensors must be reproducible with uniform size and shape. 
Furthermore, it is essential to be able to re-use the biosensor. 
Therefore, regeneration protocols have to be developed. Lack of 
sensitivity in some applications is a concern as perceptible colour 
change is difficult to measure, which restricts their application to 
biological sample analysis in comparison to other analytical 
methods such as fluorescence and chemiluminescence.51 A variety 
of approaches have been introduced to address some of these 
limitations.51,116–118 
 
Kim and colleagues have recently introduced a new approach to 
enhance AuNPs platform sensitivity based on centrifugation and 
silver enhancement. This development resulted in a threefold 
improvement in detection limit, but the additional steps are time 
consuming and add to costs.119 Moreover, an approach by Valentini 
et al. for the colorimetric detection of the cancer-related point 
mutation was demonstrated using AuNPs combined with signal 
enhancement on the surface of paramagnetic microparticles. This 
simple colorimetric assay is sensitive (with a limit of detection in the 
low picomolar range) and instrument-free. Its naked-eye detection, 
small sample volumes, and isothermal (PCR-free) amplification, 
make the assay suitable for point-of-care applications.120 
Integration of LSPR with identification techniques (e.g., SERS) is 
another way allowing improvement of the AuNPs assay detection 
limits.36,121 
 
In the development of colorimetric sensing assays for routine use in 
biological samples, it is important to take cognisance of the fact 
that the interferences caused by cellular components and 
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macromolecules can affect the analytical performance of the 
sensor. Nevertheless, some reports of measurement of enzyme 
activity via AuNPs in cell lysates have shown promising results.98,122  
In complex samples, such as serum, saliva or cerebrospinal fluid, 
AuNPs surfaces are exposed to biomolecules, cells, and tissues 
which can potentially impair the performance of the measurement. 
The occurrence of nonspecific binding and ligand exchange should 
be taken into account when developing biosensing applications. In 
addition, ligand exchange may occur in the presence of high 
concentrations of other thiolated molecules (e.g., intracellular 
glutathione).123 These interferences must be carefully studied 
during method validation. Potential interferences can occur when 
charge bearing ligands interact non-specifically with other charged 
biomolecules.  
 
In order to avoid or at least minimise ligand exchange and 
nonspecific binding, it is  essential to use a mixture of ligands, 
including PEGylated alkanethiols.124 The ethylene glycol group is 
characterised by being hydrophilic and uncharged at physiological 
pH imparting high stability and low nonspecific binding to metal 
NPs.125 The stability imparted to the NPs solution is possibly due to 
the flexibility of the ethylene glycol groups, which prevents 
aggregation. Lévy and his co-workers demonstrated that the mixed 
matrix method provides remarkable resistance against ligand 
exchange for a caspase 3 protease sensor, while not affecting its 
function.126 Long-term studies on the impact of these factors on 
analytical performance and shelf life of nanosensors are needed in 
order to establish their reliability.127 In addition, issues of AuNPs 
stability in high ionic strength solutions should also be taken into 
consideration and addressed. Recently, Cheng et al.  have described 
a method for the detection of Ochratoxin in which paper-based 
readout is used to improve the sensitivity and accuracy of AuNP 
aggregation based colorimetric biosensor.128 The Integration of 
labelled AuNPs in microfluidics testing device is another important 
concern to pave the road to efficient strategies with enhanced 
performance and reduced complexity, e.g., Aptamers were 
tethered to AuNPs as part of an lateral flow assay-like dry-reagent 
assay strip to detect thrombin.129 
 
Conclusions 
AuNPs enzymatic colorimetric assays are challenging conventional 
detection systems as they are simple methods that only require a 
few steps for the detection of target molecules. Furthermore, no 
sophisticated instrumentation is required, and they could be 
developed into suitable near patient testing platforms. The key 
objective in these assays is to control AuNPs aggregation or 
dispersion that is determined by inter-particle attractive and 
repulsive forces. A variety of factors including the type of target 
molecule or enzyme, the recognition ligand and the transduction 
method can affect the sensitivity of AuNPs-based sensors. Their 
unique optical properties make them suitable for high throughput 
and multiplexed detection techniques. The recent successes of 
multidisciplinary research in nanoscience have resulted in increased 
investment in the field of colorimetric biosensors for point of care 
medical devices. Advances in proteomics and genomics research for 
biomarkers, sensor development, imaging techniques and 
biomedical science will result in better control and design of 
nanometre-sized materials. Better understandings of the 
interactions that control the performance of the materials at this 
scale are required for optimum design and performance. The 
development of novel chemical tools for the study of organised 
assembly and modification of nanostructures will result in 
advancement in the design of these biosensors. Although there are 
many enzymes used in drug screening and biomedical applications, 
not all categories have attracted the same level of attention.  The 
majority of nanosensors have been developed for hydrolysases 
(e.g., lysozyme)130–132 and proteases (e.g. thrombin)81,133,134 because 
of their well-known biochemical characteristics and facile binding to 
synthetic peptide substrate probes.131,135 There are, however, other 
groups of enzymes (e.g., epimerase, γ-glutamyltransferase, 
glutamine synthetase) that can be used as potential diagnostic or 
prognostic markers of specific diseases, yet their activity has 
infrequently been measured in AuNPs-based enzyme assays. A 
focus on these neglected enzyme groups (isomerases, transferases, 
and synthetases) should not only extend the spectrum using AuNPs-
based enzyme assays, but also inspire the development of AuNPs-
based assays for new targets.136–138 
Despite the benefits presented by these nano diagnostic systems, 
there is still a long way to go before the extensive application of 
colorimetric AuNPs can offer effective diagnostic  tests that can be 
translated into the laboratory or testing near patient setting.139 
There are remaining challenges and these include the following: 
stability issues encountered in high ionic strength samples, such as 
in serum and urine that induce non-specific AuNPs aggregation and 
hence trigger associated colour change especially bare AuNPs are 
deployed. The lack of integration into simple platforms that are 
capable of eliminating the need for sample pre-treatment, and to 
prevent possibility of ligand exchange and nonspecific interactions 
in complex matrices are major drawbacks. These limitations are 
currently being addressed. Nonetheless, there has been some effort 
in developing these technologies for point-of-care applications. For 
example, the Au-nanoprobe system for the characterisation of 
DNase I activity has been integrated into a lateral flow platform for 
fast and easy to use of measurements on test strips.140  This field is 
still in need of innovation, especially in exploiting the remarkable 
properties of AuNPs for biosensing applications. One such 
innovation is incorporating these biosensing platform into 
smartphones or similar portable electronic devices for mobile 
sensing.141  
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Table 2. Summary of AuNP-Based LSPR assays for the detection of a variety 
of targets using CL aggregation in presence of cross linker. 
 
 
 
 
 
 
 
 
 
 
Table 3. Summary of AuNP-Based LSPR Assays for various detection targets 
(CL aggregation) without cross linker. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Target Cross linker Detection 
limit 
Ref. 
Kinase γ-biotin-ATP n/a 89 
Thrombin, 
lethal factor 
two-cysteine-containing 
peptide 
5nM 
25 nM 
142 
Factor XIII Ɛ-(γ-glutamyl) lysine 
bonds 
0.01 U/ mL 143 
Histone methyl 
transferase 
Acetyltransferae 
IgG antibody 0.2 nM 
 
0.5 nM 
144 
Thermolysin 
 
 
Acetylated Cys residues at 
both peptides termini 
90 zg mL-1 
(˂380 
molecule) 
10 ag mL-1 
56 
MMP 7 peptide substrates 
with hexahistidine at both 
ends 
3 nM 145 
Phospho Lipase 
A2 
synthetic polypeptide 
JR2KC2 
700 pM 146 
Thrombin AuNP-conjugated 
polyelectrolyte 
10 nM 147 
Horse Radish 
Peroxidase 
ferrocene dimer 1.75 ag/mL 112 
Telomerase Cysteine 27 cells/μL 148 
β-Lactamase dithiol-modified 1,2-bis (2-
amino ethoxy) ethane 
n/a 87 
LSD1 Nuclease Biotin-Avidin 
polyanionic ssDNA 
130 pM 62 
95 
ALP 
Pyrophosphatase 
Apyrase 
Zn n/a 149 
Trypsin/MMP-2 Polypeptide 5nM 99 
DPP-IV Tripeptide 70 U/L 150 
human RecQ4 
Helicase 
DNA base pair n/a 151 
Lysine 
decarboxylase 
Histidine 
decarboxylase 
Cadaverine 
 
Histamine 
2.5 µM 
 
0.9 µM 
 
152 
Target Detection limit Ref. 
DNAse I n/a 90 
Restriction endonuclease DNA 
methyltransferase 
n/a 153 
T4 polynucleotide kinase n/a 154 
Acetyl Choline Esterase 0.6 U/L 155 
DNA (cytosine-5) 
methyltransferase 
8-oxoguanine glycosylase 
0.5 U/mL 
 
0.7 U/mL, 
156 
ALP n/a 88 
Aminopeptidase N n/a 157 
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Table 4. Summary of AuNP-Based LSPR assays for various detection targets 
(NCL aggregation) 
 
 
 
 
 
 
           Table 5 Summary of AuNPs plasmonic ELISA and immunoassays 
 
 
 
Table 6 Miscellaneous mechanisms 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Target Detection limit Sample 
type 
Ref. 
λ exonuclease n/a n/a 94 
MMP-7 5 nM (0.1 mg mL-1). n/a 158 
Lysozyme 80 pg mL-1 Serum 130 
Thrombin 0.04 pM Plasma 133 
Kinase (PKA, PKCα, and 
MAPKAPK-2) and its inhibitors 
n/a Cell lysate* 
B16 
melanoma 
98, 
159 
c-Src tyrosine kinase 
(gold nanorods) 
n/a n/a 160 
Lipase 2.8 × 10 mg/mL Fermentatio
n broth of 
Bacillus 
subtilis 
161 
Trypsin 
MMP-2 
1.25 x 10-2 
20 ng/ mL 
n/a 162 
MMP-1, MMP-2 and MMP-7 n/a Plasma 163 
ALP 0.01 U/mL n/a 164 
ALP 10 units/L serum 165 
Thrombin 10 nM n/a 81 
Cathepsin B 5 nM n/a 166 
Pyrophosphatase 0.010 U n/a 167 
Acetyl choline esterase 1.0 mU mL − 1 CSF 155 
Immunoglobulin A1 protease n/a n/a 168 
Choline Esterase 
(gold nanorods) 
0.018 µU mL-1 
 
serum 
 
169 
 
β-galactosidase  
β-glucosidase  
9.2 nM 
22.3 nM 
 
n/a 170 
Penicillin G acylase 0.007 mg mL-1 n/a 171 
Telomerase 1 HeLa cell µL−1 n/a 172 
S-Adenosyl homocysteine 
hydrolase 
100 u/L  
(~ 6nM) 
n/a 173 
Caspase-3 0.005 mg  
 
Jurkat T 
lymphocyte 
cells 
174 
Telomerase  1000 Hela cells n/a 175 
Adenosine deaminase 1.526 U L−1 n/a 176 
ALP 16 nM n/a 96 
DNA adenine methylation 
methyltransferase 
n/a 0.3 units/mL 177 
Adenosine Deaminase n/a n/a 178 
Heparinase III Serum & plasma n/a 179 
Target Detection limit Sample type Ref. 
Horse Radish 
Peroxidase 
350 fM n/a 184 
PSA 1×10-18 g/ml Serum 110 
PSA 93 aM n/a 111 
Urease 30 amol n/a 112 
Target Nanomaterial Detection 
limit 
Sample 
type 
Ref. 
PSA Au nanostars 10 -18 g mL-1 n/a 109 
ALP Gold/Silver 
Core/Shell 
Nanorod 
3.3 mU 
mL−1. 
 
serum 108 
Tyrosinase AuNPs seeds 10 units  
(100 µg/mL) 
 
n/a 107 
MMP-7 Combined 
peptide–AuNP 
probe and 
nitrilotriacetic 
acid (NTA) 
modified chip 
0.097ng/ml 
(4.8 pM) 
Cell culture 
supernatant 
185 
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